https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
ing tight junction proteins as biomarkers of disease activity in MS and further investigations in larger cohorts are needed to clarify this issue. Higher levels of occludin suggest an increased permeability of the BBB and/or the intestinal barrier in MS patients. The reduction of occludin after 12 months on DMTs might reflect repair of these barriers upon treatment. However, plasma levels of ZO-1 and occludin could not predict clinical or MRI disease activity as determined by regression and ROC-curve analysis. Our results do n
Like
Comment
Share
